ClinicalTrials.gg
Sign In
Drug

Anti-PD-1/Anti-VEGF Bispecific Antibody MHB039A clinical trials

studies test it
3
open now
2
in phase 3
0
first study started
2024

How each study uses Anti-PD-1/Anti-VEGF Bispecific Antibody MHB039A is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Anti-PD-1/Anti-VEGF Bispecific Antibody MHB039A studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

MHB039A for Injection
2

Development codes

MHB039A
1

Studies by the year they started

3 studies that test it; most in 2025 (2)

Studies that test Anti-PD-1/Anti-VEGF Bispecific Antibody MHB039A, by start year
YearStudies
20241
20252

By phase

A phase 1/2 study counts in both.

Phase 1
2
Phase 2
3

Who runs them

Industry 3 · Other 0

Minghui Pharmaceutical (Hangzhou) Ltd (3)

Often tested with

Tested in the same studies.

Anti-B7-H3 Antibody-drug Conjugate MHB088C (1) · Anti-TROP-2/Topoisomerase Inhibitor ADC MHB036C (1)

Related medicines

As reviewed, each with the page that says it.

Studies

Open first, then newest update. How each study uses Anti-PD-1/Anti-VEGF Bispecific Antibody MHB039A is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 3

Given beside what is tested · 1 — Anti-PD-1/Anti-VEGF Bispecific Antibody MHB039A is usual care or a partner of the new treatment